Nuestra evidencia

Última actualización: 7 de junio de 2026.

Manteniendo los más altos estándares: Medicina Basada en Evidencia (MBE) y Medicina de Laboratorio Basada en Evidencia (MLBE)

En Blueberry Diagnostics, nuestro compromiso fundacional está arraigado en el avance estricto de la Medicina Basada en Evidencia (MBE) y la Medicina de Laboratorio Basada en Evidencia (MLBE).

Nos aseguramos de que cada algoritmo de diagnóstico e información analítica que ofrecemos esté anclado en datos clínicos empíricos y verificables. Demostrando este compromiso con la divulgación científica, hemos publicado los resultados de varios de nuestros propios estudios —en forma de resúmenes y pósters—, en algunos de los congresos y conferencias médicas más importantes del mundo.

Ensayos clínicos

Los ensayos clínicos son el primero paso en un largo proceso que comienza y termina con las personas.

Los ensayos clínicos son estudios de investigación realizados en personas que tienen como objetivo evaluar una intervención médica, quirúrgica o conductual, e involucran a un comité de ética y el consentimiento informado de los pacientes para garantizar el rigor médico del proceso. Son la vía principal por la cual los investigadores descubren nuevos tratamientos para las enfermedades, así como nuevas formas de detectar, diagnosticar y reducir las probabilidades de desarrollar la enfermedad.

Basamos nuestros ensayos clínicos en estudios de casos y controles, que consisten en comparar la frecuencia de exposición en un grupo de sujetos que padecen la enfermedad estudiada (casos) con respecto a otro grupo libre de esa enfermedad (controles).

Evidencia publicada

Hasta la fecha, hemos publicado los resultados de varios de nuestros propios estudios —en forma de resúmenes y pósters—, en algunos de los congresos y conferencias más importantes de todo el mundo.

Evidencia publicada relacionada con chequeos de salud para el cribado —screening— y la prevención

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Basic Health Checkup for Screening and Prevention

Background & Objective: To develop a novel non-invasive, evidence-based laboratory medicine (EBLM) test to assist doctors in assessing the main body functions, systems and metabolisms, and to evaluate its accuracy in detecting the main non-malignant, highly prevalent, morbid, cancer-precursor, and deadly diseases.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó, José D Santotoribio (Hospital Universitario Puerto Real)

European Society for Medical Oncology (ESMO) Annual Congress
Barcelona, 2024

Comprehensive Health Checkup for Screening and Prevention

Background & Objective: To develop a comprehensive non-invasive evidence-based laboratory medicine (EBLM) test to assist doctors in assessing the most body functions, systems and metabolisms, and to evaluate its accuracy in detecting the main non-malignant and malignant, highly prevalent, morbid, cancer-precursor, and deadly diseases.

Authors: José D Santotoribio (Hospital Universitario Puerto Real), Sergio J Calleja Freixes, Adrià Roca Vidalmargó

Evidencia publicada relacionada con chequeos de salud para el cribado —screening— y la prevención en diferentes sistemas y funciones corporales

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Iron Transport & Storage Function

Background & Objective: To develop a new non-invasive evidence-based laboratory medicine (EBLM) test to help doctors assess the iron transport and storage function, and evaluate its accuracy in detecting the main types of anemia (normocytic, microcytic, macrocytic), their main causes (liver disease, vitamin B12 deficiency, hemorrhage, or chronic kidney disease), and other hematological disorders.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó, José D Santotoribio (Hospital Universitario Puerto Real)

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Cardiovascular Function

Background & Objective: To develop a new non-invasive evidence-based laboratory medicine (EBLM) test to help doctors assess cardiovascular function and evaluate its accuracy in detecting the main cardiovascular diseases (CVD), as well as the 10-year risk of developing them.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó, José D Santotoribio (Hospital Universitario Puerto Real)

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Pancreatic Endocrine Function

Background & Objective: To develop a new evidence-based laboratory medicine (EBLM) test to help doctors assess pancreatic endocrine function and evaluate its accuracy in detecting the main pancreatic endocrine diseases and disorders, including insulin resistance, prediabetes, and type 2 diabetes mellitus, among others.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó, José D Santotoribio (Hospital Universitario Puerto Real)

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Thyroid Function

Background & Objective: To develop a new evidence-based laboratory medicine (EBLM) test to help doctors assess thyroid function and evaluate its accuracy in detecting the main thyroid diseases, including hypothyroidism, subclinical hypothyroidism, hyperthyroidism, and Graves' disease, among others.

Authors: Adrià Roca Vidalmargó, Sergio J Calleja Freixes, José D Santotoribio (Hospital Universitario Puerto Real)

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Parathyroid Function

Background & Objective: To develop a new evidence-based laboratory medicine (EBLM) test to help doctors assess parathyroid function and bone metabolism, and evaluate its accuracy in detecting the main parathyroid diseases, including primary hyperparathyroidism, secondary hyperparathyroidism, and hypoparathyroidism, among others.

Authors: Adrià Roca Vidalmargó, Sergio J Calleja Freixes, José D Santotoribio (Hospital Universitario Puerto Real)

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Hepatobiliary Function

Background & Objective: To develop a new evidence-based laboratory medicine (EBLM) test to help doctors assess hepatic and biliary-pancreatic exocrine function and evaluate its accuracy in detecting the main liver and biliary diseases, including chronic liver disease, steatosis, hepatitis, cirrhosis, and biliary tract disorders, among others.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó, José D Santotoribio (Hospital Universitario Puerto Real)

International Conference on Pathology and Laboratory Medicine (ICPLM)
Paris, 2024

Renal Function

Background & Objective: To develop a new non-invasive evidence-based laboratory medicine (EBLM) test to help doctors assess renal function and evaluate its accuracy in detecting the main chronic kidney disease (CKD) stages and related disorders.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó, José D Santotoribio (Hospital Universitario Puerto Real)

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Hydroelectrolytic Metabolism

Background & Objective: To develop a new non-invasive evidence-based laboratory medicine (EBLM) test to help doctors assess hydroelectrolytic metabolism and evaluate its accuracy in detecting electrolyte imbalances and related disorders.

Authors: Adrià Roca Vidalmargó, Sergio J Calleja Freixes, José D Santotoribio (Hospital Universitario Puerto Real)

Clinical Chemistry and Laboratory Medicine Congress (EUROMEDLAB)
Brussels, 2025

Prostate Function

Background & Objective: To develop a new non-invasive evidence-based laboratory medicine (EBLM) test to help doctors assess prostate function and evaluate its accuracy in detecting the main prostate disorders, including benign prostatic hyperplasia, prostatitis, and other prostate pathologies.

Authors: Adrià Roca Vidalmargó, Sergio J Calleja Freixes, José D Santotoribio (Hospital Universitario Puerto Real)

Evidencia publicada relacionada con el cribado —screening— de cáncer

American Society of Clinical Oncology (ASCO)
Chicago, 2022

Breast Cancer Screening

Background & Objective: Despite the various methods available for early breast cancer detection (mainly mammography for women between 50 and 65 years old) and their proven benefits, the morbidity and mortality from this neoplasm remain high, partly due to technical limitations and low adherence to screening programs. The objective of the present study was to evaluate diagnostic accuracy for early breast cancer detection using a modeling algorithm based on multiple blood and urine biomarkers.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó

American Society of Clinical Oncology (ASCO)
Chicago, 2022

Colorectal Cancer Screening

Background & Objective: Despite the various methods available for early colorectal cancer (CRC) detection and their proven benefits, the morbidity and mortality associated with this neoplasm remain high, partly due to technical limitations and low adherence to screening programs. In this sense, the objective of the present study was to evaluate diagnostic accuracy for early CRC detection using a modeling algorithm based on multiple blood and urine biomarkers.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó

European Society for Medical Oncology (ESMO) Gastrointestinal
Munich, 2024

Liver Cancer Screening

Background & Objective: Hepatocellular carcinoma (HCC) represents 75% to 85% of malignant liver neoplasms and is the third leading cause of cancer-related mortality worldwide. Unfortunately, HCC typically presents in advanced stages, which poses significant challenges for its treatment and management.

Authors: José D Santotoribio (Hospital Universitario Puerto Real), Sergio J Calleja Freixes, Adrià Roca Vidalmargó

European Society for Medical Oncology (ESMO) Gynaecological
Florence, 2024

Ovarian Cancer Screening

Background & Objective: Ovarian cancer ranks seventh among female cancers and eighth in cancer-related deaths in women. Despite its low incidence, its impact is considerable due to late detection and limited treatment options. Known as the "silent killer" for its nonspecific symptoms, it often leads to late diagnosis and metastasis. Therefore, early detection remains a challenge.

Authors: José D Santotoribio (Hospital Universitario Puerto Real), Sergio J Calleja Freixes, Adrià Roca Vidalmargó

European Multidisciplinary Congress on Urological Cancers (EMUC)
Lisbon, 2024

Prostate Cancer Screening

Background & Objective: Prostate cancer (PC) is the fourth most common cancer type in the world and the second most frequent in men, according to the World Cancer Research (WCRF) Foundation International.

Authors: José D Santotoribio (Hospital Universitario Puerto Real), Sergio J Calleja Freixes, Adrià Roca Vidalmargó

European Society for Medical Oncology (ESMO) Annual Congress
Barcelona, 2024

MCED Screening Checkup

Background & Objective: To develop a comprehensive non-invasive evidence-based laboratory medicine (EBLM) test to help doctors screen for multiple cancer types and hundreds of benign diseases simultaneously.

Authors: José D Santotoribio (Hospital Universitario Puerto Real), Sergio J Calleja Freixes, Adrià Roca Vidalmargó

Evidencia publicada relacionada con la confirmación diagnóstica de cáncer

American Society of Clinical Oncology (ASCO)
Chicago, 2022

Colorectal Cancer Confirmation

Background & Objective: Despite the various methods available for early colorectal cancer (CRC) detection and their proven benefits, the morbidity and mortality associated with this neoplasm remain high, partly due to technical limitations and low adherence to screening programs. In this sense, the objective of the present study was to evaluate diagnostic accuracy for early CRC detection using a modeling algorithm based on multiple blood and urine biomarkers.

Authors: Adrià Roca Vidalmargó, César Patiño Peña

International Association for the Study of Lung Cancer (IASLC)
San Diego, 2024

Lung Cancer Confirmation

Background & Objective: This malignant neoplasm is a global health problem, with high incidence, mortality, and profound socioeconomic impact due to invasive and costly diagnostic procedures. Therefore, a new non-invasive test is needed to provide confirmatory diagnosis of lung cancer. Based on this need, the objective of this study was to conduct a comprehensive meta-analysis to systematically evaluate the estimated diagnostic accuracy of our developed biomarker algorithm for confirming or ruling out lung cancer.

Authors: Sergio J Calleja Freixes, Adrià Roca Vidalmargó, César Patiño Peña